Journal article
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
Abstract
We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine. Thirteen patients 55 years and older with relapsed or refractory acute myeloid leukemia (AML) were enrolled. Oral TDZ was administered at 3 dose levels: 25 mg (n = 6), 50 mg (n = 4), or 100 mg (n = 3) every 6 hours for 21 days. Intermediate-dose cytarabine was administered on days 6 …
Authors
Aslostovar L; Boyd AL; Almakadi M; Collins TJ; Leong DP; Tirona RG; Kim RB; Julian JA; Xenocostas A; Leber B
Journal
Blood Advances, Vol. 2, No. 15, pp. 1935–1945
Publisher
American Society of Hematology
Publication Date
August 14, 2018
DOI
10.1182/bloodadvances.2018015677
ISSN
2473-9529